株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

乳癌治療薬の世界市場:2019〜2023年

Global Breast Cancer Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 762853
出版日 ページ情報 英文 137 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.99円で換算しております。
Back to Top
乳癌治療薬の世界市場:2019〜2023年 Global Breast Cancer Therapeutics Market 2019-2023
出版日: 2018年12月13日 ページ情報: 英文 137 Pages
概要

世界の乳癌治療薬市場は2022年までCAGR8%で拡大すると予測されています。併用療法、ワクチン、PARP阻害剤、CDK阻害剤など、乳癌治療の革新的アプローチが登場しています。

当レポートでは、世界の乳癌治療薬市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入するベンダーのプロファイルについてまとめています。

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市況

  • 市場エコシステム
  • 市場の特性
  • 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2017年)
  • 市場規模と予測(2017〜2022年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入者の脅威
  • 代用品の脅威
  • ライバルの脅威
  • 市場状況

第7章 製品別市場セグメンテーション

  • セグメンテーション
  • 比較
  • 標的療法
  • ホルモン療法
  • 化学療法
  • 市場の機会

第8章 顧客動向

第9章 タイプ別市場セグメンテーション

  • 非浸潤性乳管癌
  • 浸潤性乳管癌
  • トリプルネガティブ乳癌
  • 炎症性乳癌
  • 転移性乳癌

第10章 地域別動向

  • セグメンテーション
  • 比較
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域
  • 主要国
  • 市場の機会

第11章 促進因子と課題

第12章 市場動向

第13章 ベンダー環境

第14章 ベンダー分析

  • 網羅されるベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AstraZeneca
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

第15章 付録

図表
  • Exhibit 01: Years in consideration
  • Exhibit 02: Global oncology drugs market
  • Exhibit 03: Segments of global oncology drugs market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Molecules in the pipeline for different type of breast cancer
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Sales in $ millions from 2015-2017
  • Exhibit 24: Hormonal therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Hormonal therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Market opportunity by product
  • Exhibit 29: Customer landscape
  • Exhibit 30: Market share by geography 2018-2023 (%)
  • Exhibit 31: Geographic comparison
  • Exhibit 32: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: First-in-class drugs for the treatment of breast cancer approved in 2017 and 2018
  • Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Decision framework
  • Exhibit 42: New drug approvals for breast cancer
  • Exhibit 43: Patient support programs
  • Exhibit 44: Biosimilars for Herceptin and Avastin
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: List of collaborations between manufacturers for the breast cancer therapies
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: AstraZeneca - Vendor overview
  • Exhibit 53: AstraZeneca - Business segments
  • Exhibit 54: AstraZeneca - Organizational developments
  • Exhibit 55: AstraZeneca - Geographic focus
  • Exhibit 56: AstraZeneca - Key offerings
  • Exhibit 57: Eli Lilly - Vendor overview
  • Exhibit 58: Eli Lilly - Business segments
  • Exhibit 59: Eli Lilly - Organizational developments
  • Exhibit 60: Eli Lilly - Geographic focus
  • Exhibit 61: Eli Lilly - Segment focus
  • Exhibit 62: Eli Lilly - Key offerings
  • Exhibit 63: F. Hoffmann-La Roche - Vendor overview
  • Exhibit 64: F. Hoffmann-La Roche - Business segments
  • Exhibit 65: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 66: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 67: F. Hoffmann-La Roche - Segment focus
  • Exhibit 68: F. Hoffmann-La Roche - Key offerings
  • Exhibit 69: Novartis - Vendor overview
  • Exhibit 70: Novartis - Business segments
  • Exhibit 71: Novartis - Organizational developments
  • Exhibit 72: Novartis - Geographic focus
  • Exhibit 73: Novartis - Segment focus
  • Exhibit 74: Novartis - Key offerings
  • Exhibit 75: Pfizer - Vendor overview
  • Exhibit 76: Pfizer - Business segments
  • Exhibit 77: Pfizer - Organizational developments
  • Exhibit 78: Pfizer - Geographic focus
  • Exhibit 79: Pfizer - Segment focus
  • Exhibit 80: Pfizer - Key offerings
  • Exhibit 81: Validation techniques employed for market sizing
  • Exhibit 82: List of abbreviations
目次
Product Code: IRTNTR30504

About this market

Emerging novel therapies to gain traction in the market. Therapies including combination therapies, vaccines, PARP inhibitors, and CDK inhibitors are emerging as innovative approaches to treat breasts cancer. Technavio's analysts have predicted that the breast cancer therapeutics market will register a CAGR of close to 8% by 2023.

Market Overview

Rising number of patient supportive initiatives

To address the economic and emotional burden associated with cancer, manufacturers, governments, non-profit organizations, and healthcare providers are aiming at improving patient access to resources and bridge the substantial gaps in care.

Tendency of patients to prefer substitutes

Individuals with breast cancer often opt for mastectomy, lumpectomy, and radiation therapy to eliminate the tumor mass. However, efficient therapies including chemotherapy, and targeted and hormonal therapies are used to treat breast cancer. These surgeries act as substitutes and patients prefer these substitutes, which are expensive and can have a series of side effects.

For the detailed list of factors that will drive and challenge the growth of the breast cancer therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the emerging novel therapies and the rising number of patient supportive initiatives, will provide considerable growth opportunities to breast cancer therapeutics manufactures. AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, Novartis, and Pfizer are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Hormonal therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Ductal carcinoma in situ
  • Invasive Ductal Carcinoma
  • Triple-negative breast cancer
  • Inflammatory breast cancer
  • Metastatic breast cancer

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
Back to Top